Where does NanoCav, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), NanoCav, LLC ranks #21,486 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does NanoCav, LLC hold?

NanoCav, LLC holds 13 US utility patents granted between 2019 and 2025, spanning 9 technology areas.

What is NanoCav, LLC's Innovation Score?

NanoCav, LLC has an Innovation Score of 46.7 out of 100 (top 20% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is NanoCav, LLC's patent grant rate increasing or decreasing?

NanoCav, LLC's recent grant velocity is +800% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for NanoCav, LLC's patents?

NanoCav, LLC's patents average 19.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the NanoCav, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

NanoCav, LLC

Q: What technology areas does NanoCav, LLC focus on?

NanoCav, LLC's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 7 patents, ranking #1,382 of 4,144 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

USPTO PatentsView assignee record - 13 granted patents across 9 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nanocav ranks #21,486 of 49,997 tracked US assignees by granted-patent volume, with 13 patents across 9 technology areas.

#21,486
of 49,997 US assignees by volume: Top 20%
by Innovation Score (46.7/100): 19.1
avg claims per patent: +800%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R21486 · US Corporation #21,486 · 13 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 13 grants
MID-PACK #21,486/49,997
PHOTO-FINISH Nanhu Laboratory
CPC-NARROW C12N · 9 areas
INNOV-PAR 46.7/100
CLAIMS-RICH 19.1 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +800% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Nanhu Laboratory (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nanocav’s 46.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.1 pts (19%) Velocity 15.6 pts (33%) Breadth 10.6 pts (23%) Claim depth 11.4 pts (24%)

Qualcomm Incorporated · highest

85
Hyundai Heavy… · near

47
NanoCav · this assignee

47
Restore Medical · near

47
Sanuwave · near

47
Tela Bio · near

47
3D Lighting… · lowest

7

What this shows Nanocav's Innovation Score is 46.7/100 (top 20% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Nanocav?

Each dot is one of Nanocav’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nanocav’s own 19.1 claims/patent is ABOVE the 11.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Nanocav vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nanocav's grants concentrate

NanoCav, LLC is a focused PatentsView assignee: 9 CPC subclasses with 53.8% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2019. By volume, Nanocav sits between NPL Management Limited and Nature Blinds, LLC.

Nanocav's three-year grant acceleration

NanoCav, LLC shows 7 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

NPL Management

13
Nucap Industries

13
Nymox

13
Nanhu Laboratory

13
Nashville Wire Pr…

13
Natel Energy Hold…

13
Natural Ocean Well

13
Nature Blinds

13
Nanocav ◀

13

What this shows NanoCav holds 13 patents at rank #21,517, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near NanoCav

By rank, the assignees closest to #21,517 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in NanoCav's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for NanoCav, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), NanoCav ranks #1,382 of 4,144 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (47 here).

Tela Bio, Inc. 47 Sanuwave, Inc. 47 Hyundai Heavy Industries Co., Ltd. 47 Restore Medical Ltd. 47

Nanocav's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

47 Top 20% higher than 80% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

NanoCav, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	7.7%
2020	1	7.7%
2021	1	7.7%
2022	3	23.1%
2023	3	23.1%
2024	1	7.7%
2025partial year	3	23.1%

Which technologies does NanoCav, LLC patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 7

C12M - Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Fermenters 6

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 2

C07K - Peptides 1

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 1

B03C - Magnetic OR Electrostatic Separation OF Solid Materials From Solid Materials OR FLUIDS; Separation BY High-voltage Electric Fields 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

NanoCav, LLC's patent record in context - here's where to go next.

NanoCav, LLC's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 53.8% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #21,486 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare NanoCav, LLC against NPL Management Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 46.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.